🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Oncolytic Virus

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma NCT06581406Phase 2, Phase 333 sites📍 Scottsdale📍 La Jolla📍 Los Angeles Replimune, Inc. · Tests: RP2, Ipilimumab, Nivolumab Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas NCT05139056Phase 14 sites📍 Duarte📍 Stanford📍 Chicago City of Hope Medical Center · Tests: Neural Stem Cells-expressing CRAd-S-pk7, Resection PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma NCT07018518Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: PIN +anti-PD1 A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. NCT07185243NA1 site📍 Xiamen Hangzhou Converd Co., Ltd. · Tests: recombinant human IL-21-expressing oncolytic vaccinia virus injection YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases NCT07697937Phase 21 site📍 Tianjin Tianjin First Central Hospital · Tests: YH-02 PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor NCT06883149Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: PIN +anti-PD1 IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors NCT07001592Phase 11 site📍 Pittsburgh Allegheny Singer Research Institute (also known as Alleghen… · Tests: vvDD-hIL-2-RG-1 A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) NCT07190833Phase 12 sites📍 Busan📍 Busan Bionoxx Inc. · Tests: OTS-412, Hydroxyurea (HU), Hydroxyurea (HU), Hydroxyurea (HU), Hydroxyurea (HU) OH2 Injection in Combination With HX008 for Melanoma. NCT04616443Phase 1, Phase 21 site📍 Beijing Binhui Biopharmaceutical Co., Ltd. · Tests: OH2 injection, HX008 injection A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348n/a2 sites📍 La Jolla📍 Southport Replimune, Inc. · Tests: Observational study with no interventions OH2 Oncolytic Viral Therapy in Solid Tumors NCT03866525Phase 1, Phase 21 site📍 Beijing Binhui Biopharmaceutical Co., Ltd. · Tests: OH2 injection, with or without irinotecan or HX008 Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma NCT05717699Phase 11 site📍 Beijing Capital Medical University · Tests: Ad-TD-nsIL12 HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388Phase 13 sites📍 Birmingham📍 St Louis📍 Houston M.D. Anderson Cancer Center · Tests: G207 Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma NCT07398963Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD19-CAR novel oncolytic vaccinia virus A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors NCT06368921Phase 13 sites📍 Guangzhou📍 Zhengzhou📍 Jinan Guangzhou Virotech Pharmaceutical Co., Ltd. · Tests: VRT106 Clinical Study of Oncolytic Virus in Glioblastoma NCT07145047Phase 1, Phase 21 site📍 Mianyang Mianyang Central Hospital · Tests: oncolytic virus SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) NCT06889493Phase 11 site📍 Miami Peter Hosein, MD · Tests: Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites📍 Tampa📍 Durham Memgen, Inc. · Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel H101 Plus TACE for r/m HNSCC NCT07398664Phase 21 site📍 Chengdu West China Hospital · Tests: H101, TACE OH2 Injection in Melanoma NCT05868707Phase 330 sites📍 Beijing📍 Chongqing📍 Fuzhou Binhui Biopharmaceutical Co., Ltd. · Tests: OH2, Salvage chemotherapy or best supportive care A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors NCT06826313Phase 11 site📍 Guangzhou Guangzhou Virotech Pharmaceutical Co., Ltd. · Tests: VRT106 Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients NCT07211659Phase 11 site📍 Houston Theolytics Limited · Tests: THEO-260 A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas NCT06660056Phase 11 site📍 Beijing GONGCHU Biotechnology Co., Ltd · Tests: A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progress… Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation NCT07076498Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: M032 A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies NCT07231458Phase 15 sites📍 Berlin📍 Tübingen📍 Barcelona Abalos Therapeutics GmbH · Tests: ABX-001, Pembrolizumab Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma NCT05717712Phase 11 site📍 Beijing Capital Medical University · Tests: Ad-TD-nsIL12 A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC NCT07725796Phase 115 sites📍 Queen Creek📍 Bakersfield📍 Murrieta UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Tests: UGN-501 A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors NCT06311578Phase 110 sites📍 New York📍 Philadelphia📍 Pittsburgh Johnson & Johnson Enterprise Innovation Inc. · Tests: JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1 Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy